# A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

> **NCT00977561** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 9 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** figitumumab
- **DRUG:** Cisplatin (Or Carboplatin)
- **DRUG:** Etoposide
- **DRUG:** Cisplatin (Or Carboplatin)
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT00977561
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2013-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977561, "A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00977561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*